Kymos
Kymos is recorded as a service provider in 31 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 31 trials · Latest update first
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
Sponsor Agomab Spain S.L.U.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport® for the Prevention of Episodic Migraine in Adult Participants
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
An open-label, phase I/II first-in-human, dose escalation and confirmation study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and anti-tumour activity of IPN01195 as single agent in adult participants with advanced solid tumours
Sponsor Ipsen Pharma
- Start (EU)
- Latest update
- Estimated end
A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
An Integrated Phase I/II, Multicentre, Double-Blind, Randomised, Dysport and Placebo Controlled, Dose-Escalation and Dose-Finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity Followed by an Open-label Extension Period
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
A Phase I/IIa, open-label, dose finding, safety, tolerability and exploratory trial of THEO-260 in patients with high grade serous or endometrioid ovarian cancer
Sponsor Theolytics Limited
- Start (EU)
- Latest update
- Estimated end
Exploratory clinical trial to assess safety, tolerability efficacy and pharmacokinetics of CEB-01 PLGA membrane in participants with pancreatic cancer
Sponsor Cebiotex S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies
Sponsor Pharma Mar S.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of PBF-999 in the Treatment of Patients with Prader-Willi Syndrome.
Sponsor Palo Biofarma S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Treatment, Two-Sequence, Two-Period Crossover Study in Healthy Participants Under Fasting Conditions.
Sponsor Bluepharma Industria Farmaceutica S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase Ib/II multicohort trial of different schemes of PM14 in monotherapy and in combination with radiotherapy in soft tissue sarcomas and other solid tumors
Sponsor Asoc Grupo Espanol De Investigacion En Sarcomas
- Start (EU)
- Latest update
- Estimated end
- Not reported
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.
Sponsor Bluepharma Industria Farmaceutica S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chronic migraine in adults
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
Sponsor Pharma Mar S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pharmacokinetics of Nicorandil 40 mg Extended-Release Capsules: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting and Fed Conditions.
Sponsor Auxilius Pharma Sp. z o.o.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohn’s Disease
Sponsor Agomab Spain S.L.U.
- Start (EU)
- Latest update
- Estimated end
A Single-Dose, Randomized, Open-Label, Crossover, Exploratory Bioavailability Study in Healthy Volunteers of Two Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) and Two Diamicron® MR Tablets 60 mg (I.R.I.S.) under Fasting and Fed Conditions and Oral Solution of 60 mg Gliclazide (I.R.I.S.) under Fasting Conditions.
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
- Not reported
First-in-paediatrics, open label, exploratory, externally controlled clinical trial to evaluate safety, efficacy and pharmacokinetics of 7-ethyl-10-hydroxy-camptothecin (SN-38) formulated as a biocompatible polymeric nanofiber membrane (CEB-01) for treatment, in addition to standard of care, of paediatric patients from birth to less than 18 years of age with a locally resectable tumours in comparison to standard of care.
Sponsor Cebiotex S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Bioequivalence of Ulipristal Acetate 30 mg Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.
Sponsor Laboratorios Leon Farma S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Kymos?
The 2026-10-09 snapshot links Kymos to 31 distinct CTIS trials. Recorded services include Laboratory services, Plasma samples bioanalysis for PK, Pharmacokinetic testing (in blood samples), PK testing lab. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Kymos?
The most frequently recorded therapeutic areas are Neurology, Solid Tumor Oncology, Dermatology, Gastroenterology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Kymos conducted?
The linked trials record locations in 13 countries, including Spain, Portugal, France, Germany, Italy. These are trial locations, not confirmed office locations or countries where Kymos delivered services.
What can this page tell me about Kymos's trial experience?
Browse 31 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Kymos. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Kymos S.L.